M. Falk

发表

Irradiated fibroblasts protect burkitt lymphoma cells from apoptosis by a mechanism independent of BCL‐2

G. Bornkamm, L. Hültner, C. Gregory, 1993, International journal of cancer.

Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype.

G. Lenoir, P. Krammer, K. Debatin, 1992, Blood.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations far upstream of c-myc.

C. Croce, F. Haluska, H. Hameister, 1992, Cancer research.

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.

M. Socinski, F. Shepherd, A. Szczesna, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of consolidation high-dose chemotherapy (HDCT) with ifosfamide, carboplatin and etoposide followed by peripheral blood stem cell rescue (PBSCR) in chemosensitive patients with metastatic soft tissue sarcomas.

W. Hiddemann, R. Issels, M. Schlemmer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular analysis of Hodgkin's disease‐derived cell lines

V. Diehl, H. Tesch, M. Jücker, 1988, Hematological oncology.

Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications.

V. Diehl, M. Pfreundschuh, C. Fonatsch, 1985, Cancer surveys.

Improving stable transfection efficiency: antioxidants dramatically improve the outgrowth of clones under dominant marker selection.

M. Pawlita, A. Polack, M. Brielmeier, 1998, Nucleic acids research.

Apoptosis in the Apo-1 system

I. Behrmann, P. Möller, W. Falk, 1991 .

Epstein-Barr virus terminal protein gene transcription is dependent on EBNA2 expression and provides evidence for viral integration into the host genome.

G. Lenoir, U. Zimber-Strobl, G. Bornkamm, 1990, Current topics in microbiology and immunology.

Epstein-Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein-Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines.

M. Pawlita, W. Hammerschmidt, B. Kempkes, 1996, The Journal of general virology.

Apoptosis in Burkitt lymphoma cells is prevented by promotion of cysteine uptake

R. Issels, M. Brielmeier, G. Bornkamm, 1998, International journal of cancer.

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

P. Ellis, A. Price, Y. Cormier, 2011, Journal of Cancer Research and Clinical Oncology.

Phenotype versus immunoglobulin and T‐cell receptor genotype of Hodgkin‐derived cell lines: Activation of immature lymphoid cells in Hodgkin's disease

V. Diehl, H. Tesch, C. Fonatsch, 1987, International journal of cancer.

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

R. Plummer, B. Hendriks, G. Shapiro, 2021, British Journal of Cancer.

c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.

B. Kempkes, A. Polack, G. Bornkamm, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Establishment of two permanent human bone marrow stromal cell lines with long-term post irradiation feeder capacity.

P. Dörmer, G. Reisbach, P. Meissner, 1994, Blood.

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

R. Plummer, B. Hendriks, G. Shapiro, 2021, British Journal of Cancer.

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types

B. Hendriks, N. Terranova, M. Jansen, 2020, Cancer Chemotherapy and Pharmacology.

Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.

W Hiddemann, U. Aydemir, W. Hiddemann, 2001, European journal of cancer.

Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb.

P. Lichter, F. Haluska, G. Lenoir, 1992, Human molecular genetics.

Efficacy of Consolidation High-Dose Chemotherapy with Ifosfamide, Carboplatin and Etoposide (HD-ICE) Followed by Autologous Peripheral Blood Stem Cell Rescue in Chemosensitive Patients with Metastatic Soft Tissue Sarcomas

W. Hiddemann, R. Issels, M. Schlemmer, 2007, Oncology.

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.

M. Socinski, F. Shepherd, A. Szczesna, 2015 .

Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.

W. Hiddemann, R. Issels, C. Wendtner, 2001, European journal of cancer.

Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation.

P. Choyke, P. Pinto, B. Turkbey, 2017 .

Initial response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) in high-risk soft tissue sarcomas (HR-STS) of adults and its correlation to survival parameters

W. Hiddemann, M. Reiser, R. Issels, 1999 .

Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC).

Y. Cormier, C. Butts, D. Soulières, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease

P. Ellis, Colum J Smith, C. Butts, 2007 .